Mr. Chairman, ladies and gentlemen, with great pleasure I like to welcome you in the cityofGroningen and hope that you will have an enriching and enlighten ing discussion on the conference theme on risk management in blood trans fusion. The organisation of this symposium aims at scientific networking by discussing in an international forum the most important themes of current interest in relation to the state of the art in transfusion medicine. Dr. Cees Smit Sibinga took the initiative in 1976 to start organising the blood bank symposia as they were named in the beginning. Without doubt these symposia have contributed considerably to the development of transfusion medicine. To illustrate the fact that these symposia came to my attention I recollect that I have attended the symposium in 1978, chaired by Dr. Leo Vroman, in my capacity in those days of alderman deputy mayor of the city. So, it has been a long time since. After having been away from Groningen for 18 years I have been inaugurated last week as a mayor and it is a plcasure to be again in your midst. The scries of annual symposia on blood transfusion have contributed to mark the city of Groningen on the map of the international scientific world. A great number of prestigious institutes all over the world involved in the development of transfusion medicine have linked to Groningen and we are proud of that.
Reihe
Auflage
Sprache
Verlagsort
Zielgruppe
Für Beruf und Forschung
Research
Illustrationen
Maße
Höhe: 235 mm
Breite: 155 mm
Dicke: 14 mm
Gewicht
ISBN-13
978-1-4419-4822-9 (9781441948229)
DOI
10.1007/978-1-4757-3009-8
Schweitzer Klassifikation
I. Perception of Risk.- Does Perceived Risk Withhold People from Donating Blood?.- Managing Risks from an Insurer's Perspective.- Bad Blood or the Elixir of Life? Perceived Risk of Blood Transfusions.- The Role of Cost-Effectiveness Analysis in Defining Transfusion Medicine Policy.- II. Management of Infection Defined Risks.- Risks of Transfusion-Transmitted Infection: A Comparative Analysis of Then and Now.- Prevention of Transfusion Transmissible Infections: The Impact of the Recent Past on Current Decision Making.- Management of Infection-Defined Risks.- Closing the Window of Early HIV Infection by Incorporation of HIV p24 Ag Detection.- GAT Testing: Added Value?.- III. Management of Immune Defined Risks.- The Role of T and B Cells in Transfusion-Related Immune Reactions: Cytokines and the Removal of Apoptotic Material.- Involvement of B-cells in Peripheral Scrapie Pathogenesis.- Alternative Approaches to Prevention of Alloimmunisation: A Virtue of Reality?.- Transfusion-Associated Immunodulation in Cancer Recurrence and Postoperative Infection: Meta-Analyses of Randomised Controlled Trials.- Does General Leukodepletion Provide Any Better Outcome?.- IV. Risk Management in Clinical Practice: Optimal vs Maximal.- Haemovigilance: An Approach to Risk Management and Control.- Evidence-Based Transfusion Medicine: A Fundamental Part of Risk Management.- Safety and Supply Issues from Consumers Point of View.- The Value of Education to Improve Perception, Acceptance and Communication of Transfusion-Related Risk.- This is the Bloody Limit.- The Virtue of Reality: Global Strategies in the Management of Transfusion-Related Risks.
